Locations:
Search IconSearch
September 17, 2021/Cancer

Techniques and Lessons Learned: What to Know About Single-Port Extraperitoneal Radical Prostatectomy

Early experiences and outcomes on the brink of 200 cases

Single-port robot

Cleveland Clinic was the first U.S. medical center to begin using the single-port (SP) robot for urologic procedures in late 2018. Since then, experts at Glickman Urological & Kidney Institute continue to fine-tune their surgical technique.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Jihad Kaouk, MD, Director of the Center for Robotic and Image-Guided Surgery and the Zegarac-Pollock Endowed Chair in Laparoscopic and Robotic Surgery, elaborates on the benefits of performing the prostate cancer surgery extraperitoneally, noting, “By avoiding the sac in which the bowel is contained, the surgery is compartmentalized, limited to the area just around the prostate. The gas bubble in which the robotic arms work expands the peritoneum, pushing the bowel out of the way, allowing better visibility.”

In addition, the SP robotic technique avoids the steep Trendelenburg positioning, which improves recovery time and mitigates potential risks associated with such positioning, including optical nerve edema, congestion and respiratory problems during surgery. Patients undergoing the procedure with SP robotic prostatectomy lie flat. They experience a single incision, versus the five incisions required in a patient’s abdomen in previous robotic radical prostatectomy procedures.

These key differences in the SP robotic technique allow for easier extraperitoneal access, which helps avoid intra-abdominal adhesions. The technique also avoids assistant ports. Improved recovery aspects of the SP robotic procedure include decreased opioid use (70 percent of patients do not use opioids), an increase in same-day discharges with a median hospital stay of 4.8 hours, no drains and no reported ileus, with good functional and oncologic outcomes. Nearly 90 percent of patients were continent at six months.

Advertisement

The team shared their experience using the SP robot to perform extraperitoneal radical prostatectomy in 185 cases at the American Urological Association 2021 Annual Meeting.

Learn more in their virtual presentation:

SP Extraperitoneal Radical Prostatectomy: Technique and Lessons on the Brink of 200 Cases (Graphic)

Advertisement

Related Articles

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Dr. Kamath & colleagues in the lab
June 2, 2026/Cancer/News & Insight

Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response

Study serves as ‘cautionary tale’ for physicians tempted to rely on liquid biopsy results alone

Patient with nebulizer
June 1, 2026/Cancer/Innovations

Adding Novel Inhaled Agent May Improve Lung Cancer Outcomes

Direct delivery of viral-based vector KB707 to the lungs may boost anti-tumor response and help overcome immune checkpoint inhibitor resistance

Ad